Evolving Perspectives on Diagnostic Imaging in Advanced Prostate Cancer

Learn how PSMA PET reshapes prostate cancer staging, outperforms CT and bone scans, and finds recurrence even at very low PSA.

How teams use PSMA PET to stage prostate cancer: who orders, who reads, and how tumor boards refine treatment when findings conflict.

PSMA PET reshapes advanced prostate cancer care, guiding Pluvicto use and tracking response with emerging PCWG4 criteria.

Learn how FDA-approved PSMA PET tracers differ in prostate cancer staging and recurrence, including urinary uptake nuances that may affect post-prostatectomy detection.

Clinicians weigh PSMA PET’s strengths, limits, and tracer differences, plus when to scan after recurrence to guide salvage prostate cancer therapy.

Learn how PSMA PET sharpens staging, guides Pluvicto dosing, and avoids false-positive traps—changing treatment for advanced prostate cancer.

Learn how next‑gen prostate cancer imaging outperforms CT and bone scans, revealing micrometastases and guiding team-based treatment decisions.

Learn who reads PSMA PET scans and why a multidisciplinary team translates results into clearer prostate cancer treatment and imaging decisions.

Learn how evolving PSMA PET reporting standards reshape prostate cancer staging and influence therapy choices, from SBRT to triplet regimens.

Real-world PSMA PET use in prostate cancer reveals variable readings and PSA thresholds, prompting selective scans and ongoing trials with FDG PET.

New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA.

PSMA PET improves staging in advanced and recurrent prostate cancer, guiding shared decisions with expert interpretation and paving the way for theranostics.